These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 15261558

  • 21. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.
    Weiner HL, Cohen JA.
    Mult Scler; 2002 Apr; 8(2):142-54. PubMed ID: 11990872
    [Abstract] [Full Text] [Related]

  • 22. Mitoxantrone (Novantrone) in multiple sclerosis: new insights.
    Neuhaus O, Kieseier BC, Hartung HP.
    Expert Rev Neurother; 2004 Jan; 4(1):17-26. PubMed ID: 15853611
    [Abstract] [Full Text] [Related]

  • 23. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B.
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [Abstract] [Full Text] [Related]

  • 24. Concepts of induction and escalation therapy in multiple sclerosis.
    Rieckmann P.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S42-5. PubMed ID: 19200866
    [Abstract] [Full Text] [Related]

  • 25. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.
    Ostberg A, Pittas F, Taylor B.
    Intern Med J; 2005 Jul 01; 35(7):382-7. PubMed ID: 15958106
    [Abstract] [Full Text] [Related]

  • 26. [Immunosuppressive therapy of multiple sclerosis with mitoxantrone].
    Mauch E, Kornhuber HH.
    Fortschr Neurol Psychiatr; 1993 Dec 01; 61(12):410-7. PubMed ID: 8112704
    [Abstract] [Full Text] [Related]

  • 27. Tolerability and acceptance of prolonged low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis.
    Zecca C, Petrini L, Limoni C, Staedler C, Gobbi C.
    Eur Neurol; 2011 Dec 01; 65(1):40-5. PubMed ID: 21196739
    [Abstract] [Full Text] [Related]

  • 28. [Mitoxantrone].
    Pericot I, Montalban X.
    Neurologia; 2003 Dec 01; 18(6):318-23. PubMed ID: 12838451
    [Abstract] [Full Text] [Related]

  • 29. Immunosuppressive treatment in multiple sclerosis.
    Weiner HL.
    J Neurol Sci; 2004 Aug 15; 223(1):1-11. PubMed ID: 15261554
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.
    Singhal BS, Geeta S, Hundalani SG, Menon S.
    Neurol India; 2009 Aug 15; 57(4):418-23. PubMed ID: 19770542
    [Abstract] [Full Text] [Related]

  • 31. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
    Zwibel HL, Copolymer-1 Treatment Study Principal Investigators.
    Acta Neurol Scand; 2006 Jun 15; 113(6):378-86. PubMed ID: 16674604
    [Abstract] [Full Text] [Related]

  • 32. Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity.
    Gonsette RE, Dubois B.
    J Neurol Sci; 2004 Aug 15; 223(1):81-6. PubMed ID: 15261566
    [Abstract] [Full Text] [Related]

  • 33. Lessons from randomised direct comparative trials.
    Achiron A, Fredrikson S.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [Abstract] [Full Text] [Related]

  • 34. Current disease-modifying treatment of multiple sclerosis.
    Derwenskus J.
    Mt Sinai J Med; 2011 Feb 01; 78(2):161-75. PubMed ID: 21425262
    [Abstract] [Full Text] [Related]

  • 35. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis.
    Ytterberg C, Johansson S, Andersson M, Olsson D, Link H, Holmqvist LW, von Koch L.
    Acta Neurol Scand; 2007 Aug 01; 116(2):96-9. PubMed ID: 17661794
    [Abstract] [Full Text] [Related]

  • 36. [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].
    Ory S, Debouverie M, Le Page E, Pelletier J, Malikova I, Gout O, Roullet E, Vermersch P, Edan G.
    Rev Neurol (Paris); 2008 Dec 01; 164(12):1028-34. PubMed ID: 18808781
    [Abstract] [Full Text] [Related]

  • 37. [Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study].
    Zéphir H, de Sèze J, Dujardin K, Dubois G, Cabaret M, Bouillaguet S, Ferriby D, Stojkovic T, Vermersch P.
    Rev Neurol (Paris); 2008 Jan 01; 164(1):47-52. PubMed ID: 18342057
    [Abstract] [Full Text] [Related]

  • 38. Corticosteroids treatment.
    Pozzilli C, Marinelli F, Romano S, Bagnato F.
    J Neurol Sci; 2004 Aug 15; 223(1):47-51. PubMed ID: 15261560
    [Abstract] [Full Text] [Related]

  • 39. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P.
    Expert Rev Neurother; 2004 May 15; 4(3):455-63. PubMed ID: 15853542
    [Abstract] [Full Text] [Related]

  • 40. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep 15; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.